Carolyn Starrett Buys NeoGenomics Shares

Carolyn Starrett, a notable insider, recently purchased 14,125 shares of NeoGenomics, Inc. (NASDAQ:NEO) on June 23, 2026. This transaction was not part of a pre-planned trading program. The stock was trading near $12.90 on Friday.

Insider Buying and Selling at NeoGenomics, Inc.

In addition to Carolyn Starrett's purchase, other insider activities have been reported at NeoGenomics. On June 15, 2026, Lynn Tetrault sold 5,307 shares at an average price of $11.10 as part of a planned sale. Earlier, on June 1, 2026, Stephen Kanovsky sold 23,077 shares without a pre-planned arrangement, while John Kenny purchased 5,893 shares.

Other Institutional Activity in NeoGenomics

Several institutional investors have adjusted their positions in NeoGenomics. BlackRock, Inc. increased its holdings by 496,153 shares, bringing its total to 19,957,502 shares valued at approximately $148.1 million. First Light Asset Management, LLC, however, reduced its position by 305,085 shares, holding 9,729,978 shares worth about $72.2 million. Greenhouse Funds LLLP added 456,257 shares, resulting in a total of 9,100,103 shares valued at $67.5 million. Vanguard Portfolio Management LLC and First Trust Advisors LP both opened new positions, with 7,622,187 shares and 6,162,371 shares, respectively.

NeoGenomics, Inc. Stock Down 23.9%

Shares of NeoGenomics traded near $12.90 on Friday. The company has a market capitalization of approximately $1.46 billion and a forward P/E ratio of 30.72. NeoGenomics has experienced a 52-week low of $4.72 and a high of $13.74. Its 50-day moving average is $9.32, while the 200-day moving average stands at $10.00. The firm maintains a robust current ratio of 4.42 and a quick ratio of 3.71, with a debt-to-equity ratio of 49.29.

Recent Earnings

NeoGenomics reported revenue of $745.97 million, reflecting a growth of 11.1%. However, the company posted a net margin of -13.3% and a return on equity of -11.6%. NeoGenomics is expected to announce its next earnings results on July 28, 2026.

Analysts Set New Price Targets

Analysts have been actively adjusting their price targets for NeoGenomics. On April 29, 2026, Benchmark upgraded the stock to a 'buy' with an $11 price target, while Leerink Partners also upgraded it to a 'buy' with a $25 target. TD Cowen maintained its 'buy' rating and set a $14 target. Overall, the consensus recommendation for NeoGenomics is a 'buy', with a mean price target of $15.06 based on nine analyst opinions.

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the U.S. and the U.K. The company provides a range of diagnostic services to hospitals, academic centers, pathologists, and pharmaceutical companies. Headquartered in Fort Myers, Florida, NeoGenomics is led by CEO Anthony P. Zook and employs approximately 2,500 people.

Bottom Line

Carolyn Starrett's purchase of NeoGenomics shares highlights insider confidence in the company. Investors often monitor such transactions for insights into potential stock performance. However, it's important to remember that these insider activities are historical and may not reflect current sentiment.